Knight Therapeutics Stock Fundamentals
| GUD Stock | CAD 5.29 0.02 0.38% |
Knight Therapeutics fundamentals help investors to digest information that contributes to Knight Therapeutics' financial success or failures. It also enables traders to predict the movement of Knight Stock. The fundamental analysis module provides a way to measure Knight Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Knight Therapeutics stock.
At this time, Knight Therapeutics' EBITDA is very stable compared to the past year. As of the 26th of November 2024, Cost Of Revenue is likely to grow to about 231.6 M, while Interest Expense is likely to drop about 9.4 M. Knight | Select Account or Indicator |
Knight Therapeutics Company EBITDA Analysis
Knight Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Knight Therapeutics EBITDA | 56.82 M |
Most of Knight Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Knight Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Knight EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Knight Therapeutics is extremely important. It helps to project a fair market value of Knight Stock properly, considering its historical fundamentals such as EBITDA. Since Knight Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Knight Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Knight Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Knight Ebitda
Ebitda |
|
According to the company disclosure, Knight Therapeutics reported earnings before interest,tax, depreciation and amortization of 56.82 M. This is 93.52% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all Canada stocks is 98.54% higher than that of the company.
Knight Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Knight Therapeutics's current stock value. Our valuation model uses many indicators to compare Knight Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Knight Therapeutics competition to find correlations between indicators driving Knight Therapeutics's intrinsic value. More Info.Knight Therapeutics is one of the top stocks in price to earning category among its peers. It also is rated as one of the top companies in revenue category among its peers totaling about 2,451,075 of Revenue per Price To Earning. At this time, Knight Therapeutics' Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Knight Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Knight Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Knight EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Knight Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Knight Therapeutics could also be used in its relative valuation, which is a method of valuing Knight Therapeutics by comparing valuation metrics of similar companies.Knight Therapeutics is currently under evaluation in ebitda category among its peers.
Knight Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Knight Therapeutics from analyzing Knight Therapeutics' financial statements. These drivers represent accounts that assess Knight Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Knight Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.1B | 705.0M | 659.7M | 595.1M | 557.7M | 617.8M | |
| Enterprise Value | 952.3M | 531.6M | 614.7M | 601.2M | 568.1M | 466.1M |
Knight Fundamentals
| Price To Earning | 133.90 X | ||||
| Revenue | 328.2 M | ||||
| EBITDA | 56.82 M | ||||
| Net Income | (16.84 M) | ||||
| Cash And Equivalents | 302 K | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 69.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.31 X | ||||
| Book Value Per Share | 7.53 X | ||||
| Cash Flow From Operations | 28.49 M | ||||
| Earnings Per Share | (0.16) X | ||||
| Price To Earnings To Growth | 2,857 X | ||||
| Target Price | 7.19 | ||||
| Number Of Employees | 725 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 576.83 M | ||||
| Total Asset | 945.49 M | ||||
| Retained Earnings | 150.89 M | ||||
| Working Capital | 251.09 M | ||||
| Current Asset | 499.48 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 945.49 M |
About Knight Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Knight Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Knight Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Knight Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.4 M | 1.3 M | |
| Total Revenue | 328.2 M | 344.6 M | |
| Cost Of Revenue | 220.6 M | 231.6 M | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.11 | 0.11 | |
| Research And Ddevelopement To Revenue | 0.05 | 0.05 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 3.05 | 3.21 | |
| Ebit Per Revenue | (0.01) | (0.01) |
Pair Trading with Knight Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Knight Stock
| 0.7 | TD-PFI | Toronto Dominion Bank | PairCorr |
| 0.67 | FTN-PA | Financial 15 Split | PairCorr |
| 0.65 | FFH | Fairfax Financial | PairCorr |
| 0.64 | NVDA | NVIDIA CDR | PairCorr |
| 0.59 | FSV | FirstService Corp | PairCorr |
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.